Fate Therapeutics Inc (FATE)

[jondoeuk]

CAT-248, an allogeneic CD70-directed CAR-NK cell therapy effectively controls CD70-positive tumor xenografts https://www.abstractsonline.com/pp8/#!/10828/presentation/3311

CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFß dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice https://www.abstractsonline.com/pp8/#!/10828/presentation/3318

Genetically modified TGF-ß dominant negative receptor and IL15 enhance Natural Killer (NK) cell mediated cytolytic activity in glioblastoma https://www.abstractsonline.com/pp8/#!/10828/presentation/3057